From being recruited through a highly competitive international search to Centre Director, Professor Eduardo Eyras has charted an impressive journey at EMBL Australia. After joining the John Curtin Sc...

For the last five years, the National Computational Merit Allocation Scheme (NCMAS) has functioned like a steady “electricity grid” for science: a somewhat predictable way to access national supercomp...

Image

EMBL and its community are deeply saddened by the death of Peer Bork, the organisation’s Interim Director General.

Nanopore direct RNA sequencing has accelerated the growth of the epitranscriptomics field, yet nanopore-based RNA modification landscapes are generally unreliable due to the heuristic and unvalidated ...

Nanopore direct RNA sequencing promises to decode the epitranscriptome by detecting multiple modifications on individual RNA molecules, but its potential for biological discovery is hampered by high f...

Single-cell RNA-seq facilitates the study of transcriptome diversity in individual cells. Here, authors introduce a tool for isoform quantification at the single-cell level using 3’ scRNA-seq data, co...

an AI researcher going back to school for immunology

James Cook University (JCU) is creating a brighter future for life in the Tropics and beyond, through education and research that makes a difference locally and globally.  We now have an opportunity a...

This Project will develop deep-learning models to predict interactions of ribonucleic acid (RNA) with other molecules. The expected outcomes are to improve prediction capabilities to decode RNA intera...

Single-molecule Workflow for Analysing RNA Modifications - comprna/SWARM

Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by the aberrant alternative pre-mRNA splicing of microtubule-associated protein tau ( MAPT ) exon 10, the inclusio...

RNA presents abundant opportunities as a drug target, offering significant potential for small molecule medicine development. The transcriptome, comprising both coding and noncoding RNAs, is a rich area for therapeutic innovation, yet challenges persist in targeting RNA with small molecules. RNA structure can be predicted with or without experimental data, but discrepancies with the actual biological structure can impede progress. Prioritizing RNA targets supported by genetic or evolutionary evidence enhances success. Further, small molecules must demonstrate binding to RNA in cells, not solely in vitro, to validate both the target and compound. Effective small molecule binders modulate functional sites that influence RNA biology, as binding to nonfunctional sites requires recruiting effector mechanisms, for example degradation, to achieve therapeutic outcomes. Addressing these challenges is critical to unlocking RNA’s vast potential for small molecule medicines, and a strategic framework is proposed to navigate this promising field, with a focus on targeting human RNAs.

Nature Human Behaviour - How bullying becomes a career tool

The CSIRO Industry PhD Program (iPhD) is a four-year research training program, focusing on applied research that benefits industry by solving real-world challenges. It aims to produce the next genera...